How I Think, How I Treat: Understanding Innovation in Multiple Myeloma-New Models for Attacking Disease Across the Clinical Spectrum

How I Think, How I Treat: Understanding Innovation in Multiple Myeloma-New Models for Attacking Disease Across the Clinical Spectrum is organized by PVI, PeerView Institute for Medical Education, Penn State College of Medicine.

Release Date: July 17, 2020
Expiration Date: July 16, 2021

Accreditation:
Physicians
The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in daily practice and clearly shows how novel antibodies, immunotherapy, and other innovative strategies have shaped a new model for myeloma care.

Educational Objectives
Upon completion of this activity, participants should be better able to:
• Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting
• Integrate novel therapeutics into the management of newly diagnosed myeloma, including for patients with smoldering disease or those with symptomatic disease regardless of transplant eligibility
• Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease
• Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma